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Abstract Encapsulating peritoneal sclerosis (EPS) is the
most serious complication of long-term peritoneal dialysis
(PD), with a mortality rate that exceeds 30%. There have
been many reports of the incidence of EPS being strongly
correlated to the duration of PD. Patients on PD for longer
than 5 years, and especially those receiving this treatment for
more than 8 years, should undergo careful and repeated
surveillance for risk factors associated with the development
of EPS. The development of ultrafiltration failure, a high
dialysate/plasma creatinine ratio, as determined by the
peritoneal equilibration test, peritoneal calcification, a persis-
tently elevated C-reactive protein level, and severe peritonitis
in patients on PD for longer than 8 years are signals that
should prompt the clinician to consider terminating PD as a
possible means of preventing the development of EPS. The
impact of the newer, biocompatible PD solutions on the
incidence of EPS has not yet been determined.
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Long-term PD and EPS
Encapsulating peritoneal sclerosis (EPS) is the most serious
complication of peritoneal dialysis (PD), with a mortality
rate that exceeds 30% [1]. There have been many reports of
EPS being strongly related to the longevity of PD [2–9].
This association has primarily been reported in Japanese
pediatric and adult patients as there are many long-term PD
patients in Japan due to the unavailability of deceased
donor transplantation.
In this review of EPS, we address the following issues:
the relationship between EPS and long-term PD, the criteria
for termination of PD in patients at risk for EPS, and the
recent prevalence of long-term PD in Japanese children and
it’s impact on the development of EPS.
Definition and clinical features of EPS
Current definitions of EPS are practical and clinically
relevant. The multiplicity of suspected etiologies and
confusion over the pathology of EPS is reflected in the
variety of descriptive terms that exist, such as peritoneal
fibrosis, calcific peritonitis, abdominal cocoon, and scle-
rosing peritonitis. The more accurate term is, in fact, EPS,
as it best describes the morphological changes that occur
[1]. Whereas the best literal definition of EPS is based on
clinical–pathological criteria, the diagnosis of EPS is most
o f t e nb a s e do nt h ec r i t e r i ae s t a b l i s h e db ya na dh o c
committee of the International Society for Peritoneal
Dialysis in which the clinical suspicion of the disorder is
confirmed by radiological findings [1].
Encapsulating peritoneal sclerosis is characterized by
partial or diffuse bowel obstruction, accompanied by
marked sclerotic thickening of the peritoneal membrane.
The clinical features vary, but they frequently include
abdominal pain, nausea, vomiting, weight loss, low-grade
fever, hemorrhagic effluent, ultrafiltration failure, ascites,
and resistance to recombinant human erythropoietin [1].
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for confirmation of the diagnosis of EPS include verification
of peritoneal thickening and encapsulation, identification of
intestinal obstruction, evidence of “cocooning”, and the
presence of calcification, as detected by ultrasound and/or
computed tomography (CT). The latter technique is pre-
ferred by the authors. The cocoon appearance is secondary to
the presence of a thick fibrous layer encapsulating the small
intestine. Although a precise pathological definition of EPS
is not currently available, a common feature appears to be a
complete loss of the mesothelium, accompanied by gross
interstitial thickening within the peritoneal membrane. This
thickened interstitium can be cellular (presumably activated
fibroblasts) or acellular (presumably interstitial collagen
deposition) in nature [1].
The Pediatric EPS Registry was initiated in Japan in
1996 with the aim of establishing better documentation on
the incidence and natural history of the disorder in a high-
risk population. Of the 843 patients under 16 years of age
who received PD between 1981 and the end of 1999, 17
were diagnosed with EPS; this is an incidence of 2.0%,
which is similar to the 0.7–2.8% incidence reported
among adults participating in large-scale national studies
[3, 9] (Table 1). The mortality associated with EPS is
reported to be 35–69%, and most survivors require long-
term parenteral nutrition because of their inability to main-
tain an adequate nutritional state by the enteral route [1–3,
5, 10].
A variety of factors are presumably involved in the
development of EPS. Although the entity is not unique
to dialysis patients, possible causal factors in those
patients who develop EPS in association with PD include
the duration of the PD, peritonitis, the acetate dialysis
solution, the glucose-based/hypertonic dialysis solution,
chlorhexidine, and plasticizers [1]. There is also the
possibility that some patients are genetically predisposed
to develop EPS when exposed to one or more of the
aforementioned etiologic agents, but this has not yet been
confirmed [1, 2]. Kawaguchi et al. concluded that pro-
longed PD duration constitutes the single most significant
risk factor for EPS and hypothesize that the most
frequent primary cause is the cumulative exposure of
the peritoneum to bioincompatible PD solutions charac-
terized by the inclusion of glucose and glucose degener-
ation products (GDPs) [2]. A history of severe peritonitis
and/or non-resolving peritonitis, especially in the long-term
PD patient, is also particularly problematic and likely
contributory [1].
The relationship between EPS and long-term PD
The relationship between long-term PD and EPS was
reported by Nomoto et al. [4] from Japan in 1996 and by
Rigby and Hawley in Australia and New Zealand in 1998
[5]. Subsequent to those publications, many other reports
have originated from Japan on the subject, with reference to
both pediatric and adult patients [6–9]. In the study by
Rigby and Hawley, the overall incidence of EPS increased
progressively with the duration of PD, with rates of 1.9,
6.4, 10.8, and 19.4% for patients on peritoneal dialysis
for <2, 5, 6, and 8 years, respectively [5]. Kawanishi and
Kawaguchi [7] found that the incidence of EPS among
patients who had been on PD for more than 60 months was
as high as 8.0%, although the overall incidence was 2.8%.
More recently, Kawanishi et al. reported an overall incidence
of 2.5% from Japan, with incidence rates of 0, 0.7, 2.7, 5.9,
5.8, and 17.2% after 3, 5, 8, 10, 15, and >15 years on
continuous PD, respectively (Table 2)[ 8]
Based on their study of pediatric patients, Hoshii et al.
reported that patients who developed EPS had all received
PD for longer than 5 years, with a mean PD duration of
10.3 years [9]. The incidence of EPS was 6.6% among all
patients on PD for longer than 5 years and 22% among
those who had received PD for longer than 10 years. Of the
17 patients (83%) who developed EPS, 14 did so after 1994
because the number of long-term PD patients increased in
Japan after that date. These data emphasize the need to pay
special attention to long-term PD patients with respect to
this disorder.
Table 1 Surveys of encapsulating peritoneal sclerosis
References Rigby [5] Nomoto [4] Kawanishi [7] Nakamoto [6] Kawanishi [8] Hoshii [9]
EPS cases/PD population 54/7374 124/7343 106/3760 256/11549 48/1958 17/843
Incidence rate 0.7% 1.7% 2.8% 2.2% 2.5% 2.0%
Mean PD duration in EPS patients (months) 52 (8–127) 82.9 87 (4–198) 99.6 (10–168) 114 (36–201) 124 ± 36
Mortality rate 56% 31.5% (1 year) 27% (1 year) 39.1% 22.9% (1 year) 12%
a
41.7% (2 years) 42% (2 years) 35.4% (2 years)
62% (3 years)
EPS Encapsulating peritoneal sclerosis; PD peritoneal dialysis
aData primarily from acute stage of illness
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As mentioned above, the second factor most widely
recognized as likely increasing the risk for EPS is
peritonitis, particularly if the peritonitis is severe, recurrent,
or non-resolving in nature [1, 2]. The combined effect of
bioincompatible PD solutions and the superimposition of
severe peritoneal inflammation caused by infection has
been suggested to be of particular importance (the “two-hit”
concept) [11]. However, many long-term PD patients do not
develop EPS despite experiencing multiple episodes of
peritonitis. Likewise, EPS is not infrequently seen in
patients who have never experienced infectious peritonitis.
Kawanishi et al. found that only 37 of 50 patients treated
for EPS had a history of peritonitis [3].
In Japanese children, the rate of peritonitis has been
reported to be 0.43 episodes per patient per year in
patients diagnosed with EPS. Although nine of 17 (53%)
patients with EPS had infectious peritonitis immediately
prior to the development of EPS, the overall peritonitis
rate in patients with EPS was not significantly higher
than the rate of 0.40 episodes per patient per year seen
in all patients registered in the Japanese Pediatric PD
registry over the same period of observation [9, 12].
Therefore, whereas peritonitis itself may be not a significant
risk factor, the risk may be different when the infection
occurs in a patient on long-term (>5 years) PD.
Prevention of EPS
In some cases, discontinuing PD and eliminating exposure
to the PD-related risk factors may prevent the development
of EPS. However, EPS has been reported to occur after the
patient has been transferred to hemodialysis (HD): in 33 of
48 (69%) adult patients with EPS reported by Kawanishi et
al. [3] and in five of 17 (29%) children with EPS reported
by Hoshii et al. [9], the EPS occurred after their withdrawal
from PD. It was assumed that the development of EPS was
probably not an effect of the withdrawal itself and that these
patients most likely would have developed EPS even if they
had continued on PD. However, it has been hypothesized
that leaving the peritoneum dry may exacerbate the
pathological mechanisms, resulting in the disorder and, in
turn, explain the relationship between the clinical appear-
ance of EPS and the termination of PD.
If one hopes to prevent the development of EPS,
potentially by terminating PD in a timely manner, it is
important to be able to identify clinical features that may
stimulate a change in dialysis modality. Unfortunately, this
strategy is complicated by the fact that EPS is characterized
by its insidious nature, with presenting symptoms that may
be vague and nonlocalizing. In addition, signs that may
potentially indicate a pre-EPS state, such as a decline in
ultrafiltration (UF) capacity or a change to a high-average or
high transport state based on a peritoneal equilibration test
(PET) evaluation, are not pathognomonic for EPS [2, 3].
In 1998, the Japanese EPS Study Group did publish
recommendations for when PD should be discontinued. The
recommendations consisted of UF failure and 6 minor
criteria [13]. Minor criteria include bloody dialysate and
calcification of the peritoneum, PD duration of longer than
8 years, a persistently positive C-reactive protein level,
recurrent peritonitis, and development of a high peritoneal
membrane transport state by PET.
In 1996, a protocol for peritoneal biopsy of children on
PD was initiated in Japan as another means by which EPS
could potentially be prevented [14]. The criteria for biopsy
consisted of the following: (1) loss of UF capacity and/or
calcification of the peritoneum on abdominal CT in patients
receiving PD for longer than 5 years or (2) all patients who
had received PD for longer than 8 years. The patients were
subsequently divided into two groups based on the
histological findings: (1) peritoneal sclerosis was charac-
terized by the absence of mesothelial cells, thickening of
the submesothelial connective tissue layers, degenerative
collagen fibers, and marked thickening of the walls of the
microvasculature with narrowing of the vascular lumen; (2)
peritoneal fibrosis was characterized by an increase of
collagen fibers, the presence of mesothelial cells, and
abundant fibroblasts. If peritoneal sclerosis was diagnosed,
PD was discontinued. In addition to the biopsy criteria,
termination of PD was considered in patients who had
received PD for longer than 8 years and who had
experienced infectious peritonitis. Finally, when patients
who changed dialysis modality initiated HD, prednisolone
(1 mg/kg daily) was prescribed to hopefully minimize any
peritoneal inflammatory process, followed by a gradual
decrease in dosage over 6 months. The use of this approach
has been associated with the absence of EPS in six patients
who had received long-term PD (9.3 ± 2.0 years) and whose
biopsies showed peritoneal sclerosis [14]. A single patient
Table 2 Incidence and outcome of EPS in relation to time on PD [9]
PD duration
(years)
Number of
patients
EPS cases
(incident rate, %)
Mortality
(%)
Recovery
(%)
<3 337 0
3 to <5 554 4 (0.7) 0 (0) 4 (100)
5 to <8 576 12 (2.1) 1 (8.3) 10 (83.3)
8 to <10 239 14 (5.9) 4 (28.6) 6 (42.9)
10 to 15 223 13 (5.8) 8 (61.5) 2 (15.3)
>15 29 5 (17.2) 5 (100) 0 (0)
Total 1958 48 (2.5) 18 (37.5) 22 (45.8)
Values are presented as the number (n), with the percentage given in
parenthesis
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of EPS that developed soon after an episode of peritonitis;
he did not have UF failure nor did he demonstrate
peritoneal sclerosis on the protocol biopsy [15].
Kawaguchi et al. published guidelines in which they
recommend that an alert should be instituted when patients
have received PD for longer than 8 years [2]. It should be
emphasized here that PD can be continued for longer than
8 years only if certain conditions can be met:
& stable dialysate/plasma creatinine (D/P Cr) ratio based
on the PET;
& no evidence of high peritoneal transport capacity;
& no requirement for frequent use of hypertonic dialysis
solutions;
& no continuous increase in serum C-reactive protein level;
& clinical stability with good appetite and no signs of
overhydration;
& absence of recurrent peritonitis;
& acceptance of increased risk for complications.
Although these criteria were primarily developed for
adults, they are probably applicable to children as well,
despite the absence of supportive pediatric data. It is hoped
that the future development of a surrogate marker for EPS
and the increased use of biocompatible dialysis solutions
will further reduce the incidence of EPS.
The recent prevalence of long-term PD in Japanese
children
In Japan, 25% of 807 children less than 16 years of age
who had received PD as of 1997 had been treated for more
than 5 years [16]. There are no similar data of long-term PD
therapy in children from other countries. For example,
approximately 80% of children who received PD and who
are registered in the dialysis database of the North
American Pediatric Renal Trials and Collaborative Studies
(NAPRTCS) terminated PD in less than 3 years, primarily
to receive a kidney transplant [17]. In Japan, however, the
number of children on long-term PD has recently decreased
because of the current policy—initiated following the
publication of the previously mentioned guidelines in
1998 [13]—of withdrawing patients from PD after a
treatment period of 8 years in order to avoid the occurrence
of EPS. In a historical context, the number of long-term
pediatric PD patients had, up to the initiation of this policy,
increased by the end of each year, with 100 patients (33%
of total patients) having received PD for more than 5 years
and 43 patients (14% of total patients) having been on PD
for more than 8 years at the end of 1997. The current policy
has resulted in a decrease in the overall number of long-
term PD patients and especially in the number of patients
on PD for more than 8 years (13 patients, 6%) at the end of
2003, despite the absence of any significant change in the
incidence of new patients.
The patient and technique survival rates of pediatric
patients in the Japanese PD registry based on Kaplan–Meier
analysis are described in Figs. 1 and 2. Patients who
received a kidney transplant or who were transferred to HD
were considered lost to observation at the time of transfer in
the calculation of patient survival rate. Patients who
received a transplant were also counted as lost to
observation in the calculation of the technique survival
rate. Patients were divided into two groups: patients starting
PD in 1981–1991 and those starting PD in 1992–2003.
Survival rate %
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Fig. 1 Patient survival rate in
children initiating peritoneal
dialysis before (broken line) and
during/after 1992 (solid line).
Cited from Honda [12]
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improved significantly in the most recent era (p<0.002),
with a 5-year patient survival rate of 92% in those patients
who had initiated PD during or after 1992. These excellent
results are similar to the 5-year survival data for the
transplant population reported by the United States Renal
Data System (USRDS) [18]. In contrast, after 8 years on
PD, the survival rate of the more recent cohort decreased to
a rate similar to that experienced by those on PD prior to
1992 (Fig. 1).
The technique survival rate for PD has also significantly
improved: at 5 years, the technique survival was 78% for
patients starting PD during or after 1992 compared to 64%
for patients on PD before 1992. However, as was the case
with patient survival, no difference in technique survival
was seen for the two eras when patients had received PD
for more than 8 years (Fig. 2). These results provide
evidence that patients on long-term PD (>5 years) are
indeed at increased risk for serious complications. In fact,
it has been suggested that informed consent be obtained
for any patient receiving PD for longer than 8 years
because of these issues, even if the patient is clinically
well and without risk factors for EPS.
The causes of death and transfer to HD for the Japanese
patients who initiated PD after 1991 are shown in Table 3.
For those patients who had received PD for more than
5 years, PD was terminated in 44 cases (29%) because the
patient underwent transplantation. Transfer to HD occurred
in 14 cases in which PD was discontinued secondary to
peritonitis and in 13 patients who discontinued PD as a
result of UF failure. Death due to peritonitis (two patients)
and EPS (one patient) was only seen in long-term PD
patients. The more recent absence of EPS as a cause for PD
termination is likely the result of a more proactive approach
by Japanese physicians to limit long-term PD.
Summary
The performance of long-term PD in Japanese children has
been a common practice because of the shortage of
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Fig. 2 Technique survival rate
in children initiating peritoneal
dialysis before (solid line) and
during/after 1992 (broken line).
Cited from Honda [12]
Table 3 Outcome and causes of PD termination in children after 1991
[12]
<5
years,
n (%)
≥ 5
years,
n (%)
Total 527 151
Continuance of PD 148 (28) 43 (29)
Transplantation 244 (46) 44 (29)
Recovery 14 (3) 1 (1)
Unknown, lost 37 (10) 8 (6)
Transfer to HD 50 (10) 40 (27)
Cause of transfer to HD Peritonitis 28 (56) 14 (35)
UF failure 7 (14) 13 (33)
Insufficient dialysis 6 (12) 5 (13)
Catheter trouble 3 (6) 0 (0)
Others, Unknown 6 (12) 8
a (20)
Death 34 (7) 15 (10)
Cause of death Peritonitis 0 (0) 2 (13)
Sepsis 1 (3) 1 (7)
Pneumonia 4 (12) 1 (7)
Cerebro-vascular
disorder
2 (6) 2 (13)
Heart failure 6 (18) 2 (13)
Pulmonary edema 4 (12) 0 (0)
Shock, sudden death 4 (12) 0 (0)
Others, Unknown 13 (38) 7
b (53)
HD Hemodialysis; UF ultrafiltration
aLong-term PD (three patients), after surgery (two), patient’s request
(two), psychological problem (one)
bConvulsion (one patient), EPS (one), unknown (two) original disease
(two), gastric perforation (one)
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in patients who have received PD for up to 5 years have
been good. In contrast, the outcome has not been nearly
as good for those patients on PD for longer periods of
time (e.g. >8 years), with the potential development of
EPS a significant concern. Based on current clinical data
in children and adults and in the absence of a reliable
marker of EPS, strong consideration should be given to
electively discontinuing PD in those patients who have
received long-term PD (possibly more than 5 years and
certainly more than 8 years) and who demonstrate risk
factors for EPS, such as UF failure, a high D/P creatinine
based on PET assessment, peritoneal calcifications, a
persistently elevated C-reactive protein level, and recur-
rent or severe peritonitis, as a possible means of
preventing EPS. Failure to do so is likely to result in a
poor patient outcome. Future research will determine
whether this scenario can be prevented with the use of
the newer, biocompatible PD solutions.
Questions on long-term PD
(Answers appear following the list of questions)
1) What are the two most common reasons, other than
transplantation, for terminating long-term PD in Japanese
children who have received PD for > 5 years?
a) Ultrafiltration failure and peritonitis
b) Ultrafiltration failure and cardiovascular disease
c) Cardiovascular disease and peritonitis
d) Fatigue of the patient or caregivers and peritonitis
e) Fatigue of the patient or caregivers and cardiovas-
cular disease
2) Which of the following statements pertaining to EPS is
correct?
a) EPSisdiagnosed onlybasedonpathologicalfindings
b) The mortality rate of EPS is significantly less than
30%
c) Peritonitis is the most frequent cause for EPS
d) Abdominal symptoms such as bowel obstruction
and peritoneal calcifications are important findings
in patients with EPS
e) EPS does not occur after the transfer from PD to
HD
3) After how many years of PD should we start to pay
attention to the possible development of EPS?
a) 3 years
b) 5 years
c) 8 years
d) 10 years
e) 12 years
4) Which of the following findings is not a reason to
consider terminating PD as a means of preventing the
development of EPS?
a) Persistently positive C-reactive protein
b) Increased D/P creatinine by PET
c) Decreased ultrafiltration capacity
d) Calcification of peritoneal membrane
e) Cardiovascular disease
5) After how many years of PD should informed consent
be considered, even in patients who are clinically well,
because of the risk of EPS?
a) 3 years
b) 5 years
c) 8 years
d) 10 years
e) 12 years
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